Nab-paclitaxel - Third-line chemotherapy in advanced gallbladder cancer.
作者信息
Patel Amol, Sirohi Bhawna
机构信息
Department of Medical Oncology, Army Hospital, Research & Referral, New Delhi 110 010, India.
Department of Medical Oncology, Apollo Proton Cancer Centre, Chennai 600 028, Tamil Nadu, India.
出版信息
Indian J Med Res. 2020 Nov;152(5):442-443. doi: 10.4103/ijmr.IJMR_2709_19.
Abstract
摘要
相似文献
1
Nab-paclitaxel - Third-line chemotherapy in advanced gallbladder cancer.纳米白蛋白结合型紫杉醇——晚期胆囊癌的三线化疗
Indian J Med Res. 2020 Nov;152(5):442-443. doi: 10.4103/ijmr.IJMR_2709_19.
2
Nab-paclitaxel: An effective third-line chemotherapy in patients with advanced, unresectable gallbladder cancer.纳武利尤单抗：晚期不可切除胆囊癌三线治疗的有效药物。
Indian J Med Res. 2020 Nov;152(5):475-481. doi: 10.4103/ijmr.IJMR_930_18.
3
Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.奈达铂紫杉醇对比既往治疗的晚期胃癌患者中的溶剂型紫杉醇（ABSOLUTE）：一项开放标签、随机、非劣效、3 期临床试验。
Lancet Gastroenterol Hepatol. 2017 Apr;2(4):277-287. doi: 10.1016/S2468-1253(16)30219-9. Epub 2017 Jan 19.
4
A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer.一项单臂 II 期临床试验，研究了每周纳米白蛋白结合紫杉醇（nab-紫杉醇）单药治疗在先前接受标准化疗的晚期非小细胞肺癌患者中的应用。
Cancer Chemother Pharmacol. 2019 Aug;84(2):351-358. doi: 10.1007/s00280-019-03843-0. Epub 2019 Apr 16.
5
Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.回顾性比较 nab-紫杉醇联合雷莫芦单抗与紫杉醇联合雷莫芦单抗作为晚期胃癌二线治疗（重点关注腹膜转移）。
Invest New Drugs. 2020 Apr;38(2):533-540. doi: 10.1007/s10637-019-00822-3. Epub 2019 Jul 2.
6
The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias.白蛋白结合型紫杉醇与卡铂联合治疗晚期鳞状非小细胞肺癌合并特发性间质性肺炎患者的安全性和有效性
Intern Med. 2018 Jul 1;57(13):1827-1832. doi: 10.2169/internalmedicine.0404-17. Epub 2018 Feb 9.
7
Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer.纳米白蛋白结合型紫杉醇作为局部晚期和转移性非小细胞肺癌二线化疗的疗效与安全性
Anticancer Res. 2017 Aug;37(8):4687-4691. doi: 10.21873/anticanres.11873.
8
First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN study.一线纳武利尤单抗联合卡铂/紫杉醇用于晚期非小细胞肺癌患者：NEPTUN 研究结果。
Cancer Med. 2021 Nov;10(22):8127-8137. doi: 10.1002/cam4.4310. Epub 2021 Oct 20.
9
Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence.纳米白蛋白结合型紫杉醇治疗晚期非小细胞肺癌的临床证据评价。
Expert Opin Pharmacother. 2019 Jan;20(1):95-102. doi: 10.1080/14656566.2018.1546290. Epub 2018 Nov 15.
10
[Nab-paclitaxel].[纳米白蛋白结合型紫杉醇]
Bull Cancer. 2015 Jun;102(6):568-76. doi: 10.1016/j.bulcan.2015.03.020. Epub 2015 May 23.
本文引用的文献
1
Nab-paclitaxel: An effective third-line chemotherapy in patients with advanced, unresectable gallbladder cancer.纳武利尤单抗：晚期不可切除胆囊癌三线治疗的有效药物。
Indian J Med Res. 2020 Nov;152(5):475-481. doi: 10.4103/ijmr.IJMR_930_18.
2
Contemporary Tailored Oncology Treatment of Biliary Tract Cancers.当代胆道癌的个体化肿瘤治疗
Gastroenterol Res Pract. 2019 Dec 18;2019:7698786. doi: 10.1155/2019/7698786. eCollection 2019.
3
Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial.吉西他滨联合奥沙利铂或吉西他滨联合顺铂治疗不可切除的胆囊癌：一项 III 期随机对照临床试验结果。
Eur J Cancer. 2019 Dec;123:162-170. doi: 10.1016/j.ejca.2019.10.004. Epub 2019 Nov 14.
4
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.吉西他滨、顺铂和 nab-紫杉醇治疗晚期胆道癌：一项 2 期临床试验。
JAMA Oncol. 2019 Jun 1;5(6):824-830. doi: 10.1001/jamaoncol.2019.0270.
5
Phase I study of weekly palliative chemotherapy with low-dose third-line paclitaxel for biliary tract cancer.低剂量三线紫杉醇每周姑息化疗用于胆管癌的I期研究。
Mol Clin Oncol. 2017 May;6(5):753-757. doi: 10.3892/mco.2017.1206. Epub 2017 Mar 30.
6
Nab-paclitaxel as alternative treatment regimen in advanced cholangiocellular carcinoma.纳米白蛋白结合型紫杉醇作为晚期胆管细胞癌的替代治疗方案。
J Gastrointest Oncol. 2016 Aug;7(4):588-94. doi: 10.21037/jgo.2016.05.01.
7
Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers.基于吉西他滨联合奥沙利铂方案序贯基于氟尿嘧啶、亚叶酸钙、伊立替康方案化疗在晚期胆管癌中的疗效
Acta Oncol. 2016 Sep-Oct;55(9-10):1168-1174. doi: 10.1080/0284186X.2016.1191670. Epub 2016 Jun 22.
8
Second-Line Palliative Chemotherapy in Advanced Gall Bladder Cancer, CAP-IRI: Safe and Effective Option.晚期胆囊癌的二线姑息化疗，CAP-IRI方案：安全有效的选择。
J Gastrointest Cancer. 2016 Sep;47(3):305-12. doi: 10.1007/s12029-016-9828-2.
9
FOLFOX-4 as second-line therapy after failure of gemcitabine and platinum combination in advanced gall bladder cancer patients.对于晚期胆囊癌患者，在吉西他滨与铂类联合治疗失败后，采用FOLFOX - 4作为二线治疗方案。
Jpn J Clin Oncol. 2016 Jan;46(1):57-62. doi: 10.1093/jjco/hyv148. Epub 2015 Nov 24.
10
Indian Council of Medical Research consensus document for the management of gall bladder cancer.印度医学研究理事会关于胆囊癌管理的共识文件。
Indian J Med Paediatr Oncol. 2015 Apr-Jun;36(2):79-84. doi: 10.4103/0971-5851.158829.
Zotero 插件